Trilobio is building affordable, modular robots plus a no-code operating system that automate a whole biology lab, sold to biologists rather than roboticists, and its founding team is one of the few pairing deep synthetic-biology and robotics expertise to attack that wedge. The hardware pulls the software: per the 2024-05-22 first call, the base Trilobot ran roughly $10K with $2K tool add-ons and $150/month for the Trilobio OS software, a price point that opens the long tail of academic and startup labs that enterprise robotics and send-out cloud labs have priced out Internal. The company frames the problem as reproducibility: an estimated 77% of biologists cannot reproduce research despite existing automation Web.
Validation is strong for the stage. Initialized Capital signed a term sheet to lead the round (per the 2024-08-02 note, with a16z and Bessemer also in diligence), and the oversubscribed $8M seed later closed with Lowercarbon Capital, Argon Ventures, 1517 Fund, Juniper and others Web. StoryHouse committed $200K from Fund I via a discounted SAFE (20% discount) alongside Julian Capital that converted into the priced round at a $25M post-money Internal. Since entry the company launched Trilobot One and Trilobio OS (October 2025) and, per internal notes, raised a ~$4.4M Seed Extension on a $50M post-money cap, roughly a 2x step-up on the entry mark; Company Health is marked Green Internal. CEO Roya Amini-Naieni is an HMC alum and the platform is deployed at the Leconte Group in the Keck Science Department of the Claremont Colleges, a direct 5C tie.
The broad lab-automation market is large but only mid-single-digit growth; the relevant wedge is the synthetic-biology automation-platform segment, which is small today (~$196M) but compounding at ~16% as AI-guided, high-throughput workflows scale Web. Trilobio's affordability angle expands the served market downward into the long tail of academic and early-stage labs that incumbents ignore, and the reproducibility problem (~77% of biologists cannot reproduce results) is a durable why-now Web.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Trilobio | Affordable modular on-prem robots + no-code OS; whole-lab automation for biologists | Seed, $8M / $25M post | — |
| Opentrons | Low-cost liquid-handling robots (OT-2); single-station pipetting focus | Later-stage, well-funded | Automates the full workflow, not just liquid handling |
| Emerald Cloud Lab | Centralized remote/cloud lab (Austin), 24/7 service model | Private, growth | On-prem ownership and lower cost vs. send-out cloud; data stays in-house |
Moat: A no-code OS layered on proprietary, low-cost modular robots creates full-stack lock-in and reaches the price-sensitive long tail of labs that pipetting-only and cloud-lab incumbents do not serve Web.
The most likely path is acquisition by a life-science tools consolidator such as Thermo Fisher, Danaher / Beckman Coulter, Agilent, or Tecan, all active acquirers of lab-automation and instrumentation assets Internal. On a $200K entry at a $25M post, the ~$50M extension cap already implies a ~2x paper mark; a mid-hundreds-of-millions strategic outcome would put the position in a 15–30x range Internal.
Follow-on intel sourced from Roya: the company completed and deployed its full platform and is opening a quick, opportunistic raise.
Intro and intel source: SH portfolio founder; SH follow-on round. Deal status: In Conversation.
Note from Roya: this quarter we built our functioning marketing funnel, engaged our sales pipeline, closed our first new deals, completed the Trilobot One and Trilobio OS, and successfully deployed them at four locations. We are raising a discreet, quick, and opportunistic ~$3M round starting November 2025 due to the investor traction we experienced from our Trilobot One commercial launch.
I will follow up with her for more info in case interesting to us for Fund II, but at the very least to gather data on the new round and valuation.
A text from Roya confirming a lead term sheet and active top-tier diligence while the round was being finalized.
Text from Roya (screenshot attached): Confidentially, we just got a term sheet from Initialized Capital to lead our round, still negotiating the terms.
Sorry for not responding to your emails sooner. I've been slammed raising the round. We are in diligence with a16z and Bessemer as well.
A diligence call on the former-employee lawsuit with the company's new counsel driving toward a fast resolution.
The ex-employee has no current equity in the company and is claiming vague unpaid salary, having left in early 2023 (around March 2023). The person filing the claim was terminated over sexual-allegation claims.
New counsel just took over from prior counsel to drive a quick resolution and is filing counter-claims shortly to force verification of the claims. The company considers the claims false: the claimant asserts the entire lab was his despite many attempts to return his belongings, alleges relationships between two founders, and attaches defamation; characterized as someone who left with sour grapes. The case was filed in December and little has happened since.
Too early to estimate costs and timing; the attorney is believed to be on contingency, and the company expects the matter to dissipate once litigation actually starts. A judge had not been found and a trial was being scheduled for February 18, 2025, with any brief a long way off. Not a deal breaker but a serious annoyance, and clearly something happened between Roya and the ex-employee.